GSK3‐ARC/Arg3.1 and GSK3‐Wnt signaling axes trigger amyloid‐β accumulation and neuroinflammation in middle‐aged Shugoshin 1 mice

• Published in: Aging cell 2020-10, Vol.19 (10), p.e13221-n/a
• Main Authors: Rao, Chinthalapally V., Farooqui, Mudassir, Madhavaram, Avanish, Zhang, Yuting, Asch, Adam S., Yamada, Hiroshi Y.
• Format: Article
• Language: English
• Subjects: Advertising executives; Age; Aging; Alzheimer's disease; amyloid‐β; Analysis; Animal models; Brain research; Cancer; Clinical trials; Cognitive ability; cohesinopathy; Dehydrogenases; Energy metabolism; Genomic instability; Hypotheses; Inflammation; Interferon; Kinases; late‐onset Alzheimer's disease; Metabolism; Middle age; Mitochondria; mitosis; mouse model; Mutation; Neurodegenerative diseases; neuroinflammation; Original; Oxidative stress; Pathology; Proteins; R&D; Research & development; Shugoshin1; Tumor necrosis factor-TNF; Wnt protein
• ISSN: 1474-9718; 1474-9726
• DOI: 10.1111/acel.13221

The cerebral amyloid‐β accumulation that begins in middle age is considered the critical triggering event in the pathogenesis of late‐onset Alzheimer's disease (LOAD). However, the molecular mechanism remains elusive. The Shugoshin 1 (Sgo1−/+) mouse model, a model for mitotic cohesinopathy‐genomic instability that is observed in human AD at a higher rate, showed spontaneous accumulation of amyloid‐β in the brain at old age. With the model, novel insights into the molecular mechanism of LOAD development are anticipated. In this study, the initial appearance of cerebral amyloid‐β accumulation was determined as 15‐18 months of age (late middle age) in the Sgo1−/+ model. The amyloid‐β accumulation was associated with unexpected GSK3α/β inactivation, Wnt signaling activation, and ARC/Arg3.1 accumulation, suggesting involvement of both the GSK3‐Arc/Arg3.1 axis and the GSK3‐Wnt axis. As observed in human AD brains, neuroinflammation with IFN‐γ expression occurred with amyloid‐β accumulation and was pronounced in the aged (24‐month‐old) Sgo1−/+ model mice. AD‐relevant protein panels (oxidative stress defense, mitochondrial energy metabolism, and β‐oxidation and peroxisome) analysis indicated (a) early increases in Pdk1 and Phb in middle‐aged Sgo1−/+ brains, and (b) misregulations in 32 proteins among 130 proteins tested in old age. Thus, initial amyloid‐β accumulation in the Sgo1−/+ model is suggested to be triggered by GSK3 inactivation and the resulting Wnt activation and ARC/Arg3.1 accumulation. The model displayed characteristics and affected pathways similar to those of human LOAD including neuroinflammation, demonstrating its potential as a study tool for the LOAD development mechanism and for preclinical AD drug research and development. In late middle age of a genomic instability mouse model (Sgo1−/+), unexpected inactivation of GSK3 leads to amyloid‐beta accumulation in the brain via two signaling axes: GSK3‐ARC/Arg3.1 axis and canonical Wnt/GSK3‐beta‐catenin axis. This study cautions GSK3 inhibition in the middle age for possibly triggering late‐onset Alzheimer's disease.